文献速递炎症性肠病

炎症性肠病患者英夫利西单抗静脉转皮下切换后复发风险分层工具

A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases.
PubMed 文献 · Am J Gastroenterol · 2025-04-07

本研究利用前瞻性多中心试验数据,对98例炎症性肠病(IBD)患者从静脉英夫利西单抗转换为皮下制剂后的药代动力学与药效学进行分析,识别出英夫利西单抗清除率和粪便钙卫蛋白为复发的独立预测因子,并构建两项风险评分将患者分为低风险(复发概率<19%;75/98;77%)和高风险(≥19%;23/98;23%)两组,模型区分复发与否的AUC为0.83(95% CI 0.71-0.93)。

要点

  • 英夫利西单抗清除率和粪便钙卫蛋白是切换后复发的独立预测因子。
  • 两项风险评分将患者分为低风险(<19%复发概率;75/98;77%)和高风险(≥19%;23/98;23%)。
  • 药代动力学-药效学模型区分复发与否的AUC为0.83(95% CI 0.71-0.93)。

核心结论

  • 切换前英夫利西单抗清除率和粪便钙卫蛋白可准确预测静脉转皮下英夫利西单抗后的复发。
  • 交互式风险分层工具有助于确认分层医学方法以改善IBD的英夫利西单抗治疗。

研究设计与样本

  • 利用前瞻性多中心试验数据,纳入98例从静脉转换为皮下英夫利西单抗的IBD患者。
  • 通过贝叶斯 forecasting 从切换前样本和群体药代动力学模型估算每例患者的英夫利西单抗清除率。
  • 进行药效学建模以评估切换后复发的切换前预测因子。

主要发现

  • 英夫利西单抗清除率和粪便钙卫蛋白被确定为复发的独立预测因子。
  • 两项风险评分将患者分为低风险(复发概率<19%;75/98;77%)和高风险(复发概率≥19%;23/98;23%)两组。
  • 风险评分的敏感性为0.75(95% CI 0.48-0.93),特异性为0.87(95% CI 0.77-0.93),阳性预测值为52%(95% CI 31-73%),阴性预测值为95%(95% CI 87-99%)。
  • 药代动力学-药效学模型区分有和无复发患者(P < 0.0001),受试者工作特征曲线下面积为0.83(95% CI 0.71-0.93)。

关键数值与推荐

  • 复发定义为临床复发(部分Mayo评分>2或Harvey-Bradshaw指数>4导致治疗升级)或切换时粪便钙卫蛋白增加≥150 μg/g。
  • 低风险组定义为复发概率<19%(75/98;77%),高风险组定义为复发概率≥19%(23/98;23%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A subcutaneous formulation of infliximab was recently approved for maintenance therapy of inflammatory bowel disease (IBD). However, limited clinical experience, particularly with patients on escalated intravenous infliximab regimens, poses challenges for the transition to subcutaneous therapy. We investigated the pharmacokinetics and pharmacodynamics of subcutaneous infliximab to identify early predictors of relapse on switching. METHODS: We repurposed data from a prospective, multicenter trial involving patients with IBD switching from intravenous to subcutaneous infliximab. We estimated each patient's infliximab clearance using Bayesian forecasting from a preswitch sample and a population pharmacokinetics model. We performed pharmacodynamics modeling to evaluate preswitch predictors of postswitch relapse. Relapse was defined as clinical recurrence (partial Mayo score >2 or Harvey-Bradshaw Index >4 leading to therapeutic escalation) or an increase in fecal calprotectin ≥150 μg/g on switching. RESULTS: Using data from 98 patients with IBD, we identified infliximab clearance and fecal calprotectin as independent predictors of relapse. A 2-item risk score stratified patients into the low-risk (<19% probability of relapse; 75/98; 77%) and high-risk (≥19% probability of relapse; 23/98; 23%) groups (sensitivity 0.75 [95% CI 0.48-0.93], specificity 0.87 [95% CI 0.77-0.93] positive predictive value 52% [95% CI 31-73%], negative predictive value 95% [95% CI 87-99%]). Our pharmacokinetics-pharmacodynamics model classified patients with and without relapse ( P < 0.0001) with an area under the receiver operating characteristic curve of 0.83 (95% CI 0.71-0.93). DISCUSSION: Preswitch infliximab clearance and fecal calprotectin are accurate predictors of relapse after switching to subcutaneous infliximab. An interactive risk stratification tool facilitates confirmation of a stratified medicine approach to improve infliximab therapy in IBD.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Hoffert Y, Wang Z, Fumery M, et al. A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases. Am J Gastroenterol. 2025. PMID: 40192145. doi:10.14309/ajg.0000000000003466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。